• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Alto Neuroscience Inc.

    3/16/26 6:44:48 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANRO alert in real time by email
    S-8 1 tm268235d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on March 16, 2026

     

    Registration No. 333-   

     

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

     

    FORM S-8 

    REGISTRATION STATEMENT 

    UNDER 

    THE SECURITIES ACT OF 1933

     

     

    Alto Neuroscience, Inc. 

    (Exact name of registrant as specified in its charter)

     

     

    Delaware   83-4210124
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)
       
    650 Castro Street, Suite 450
    Mountain View, CA
      94041
    (Address of Principal Executive Offices)   (Zip Code)

     

     

    Alto Neuroscience, Inc. 2024 Equity Incentive Plan 

    Alto Neuroscience, Inc. 2024 Employee Stock Purchase Plan 

    (Full titles of the plans)

     

    Amit Etkin, M.D., Ph.D. 

    President and Chief Executive Officer 

    Alto Neuroscience, Inc. 

    650 Castro Street, Suite 450 

    Mountain View, CA 94041 

    Tel: (650) 200-0412 

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Divakar Gupta 

    Christina T. Roupas 

    Courtney M.W. Tygesson 

    Madison A. Jones 

    Cooley LLP 

    110 North Wacker Drive

    Suite 4200 

    Chicago, IL 60606 

    Tel: (312) 881-6500

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

     

    Large accelerated filer ¨ Accelerated filer ¨
           
    Non-accelerated filer x Smaller reporting company x
           
        Emerging growth company x

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This registration statement on Form S-8 (this “Registration Statement”) registers an aggregate of 1,915,411 shares of common stock, par value $0.0001 per share (“common stock”), of Alto Neuroscience, Inc. (the “Registrant”) consisting of (i) 1,596,176 additional shares issuable under the Registrant’s 2024 Equity Incentive Plan (the “2024 Plan”) effective January 1, 2026, by operation of the 2024 Plan’s “evergreen” provision, and (ii) 319,235 additional shares issuable under the Registrant’s 2024 Employee Stock Purchase Plan (the “2024 ESPP”) effective January 1, 2026, by operation of the 2024 ESPP’s “evergreen” provision.

     

    Pursuant to General Instruction E to Form S-8, this Registration Statement incorporates by reference the Registrant’s registration statements on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on February 6, 2024 (File No. 333-276901) and March 20, 2025 (File No. 333-285978) as relating to the 2024 Plan and 2024 ESPP, and except to the extent supplemented, amended or superseded by the information set forth herein.

     

    PART I 

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information called for by Part I of Form S-8 is omitted from this Registration Statement in accordance with Rule 428 of the Securities Act of 1933, as amended (the “Securities Act”), and the instructions to Form S-8. In accordance with the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act.

     

    PART II 

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

     

    (a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on March 16, 2026; and

     

    (b) The description of the Registrant’s common stock contained in Exhibit 4.5 in the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 20, 2025, including any amendment or report filed with the Commission for the purpose of updating such description.

     

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information, or portions thereof, which are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

     

     

     

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Entities comprised of partners and associates of Cooley LLP beneficially own an aggregate of 57,569 shares of the Registrant’s common stock.

     

    Item 6. Indemnification of Directors and Officers.

     

    Section 145 of the Delaware General Corporation Law authorizes a court to award, or a corporation’s board of directors to grant, indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act. The Registrant’s amended and restated certificate of incorporation permits indemnification of its directors, officers, employees and other agents to the maximum extent permitted by the Delaware General Corporation Law, and the Registrant’s amended and restated bylaws provide that the Registrant will indemnify its directors and executive officers and permit it to indemnify its other officers, employees, and other agents, in each case to the maximum extent permitted by the Delaware General Corporation Law.

     

    The Registrant has entered into indemnification agreements with its directors and executive officers, whereby it has agreed to indemnify its directors and executive officers to the fullest extent permitted by law, including indemnification against expenses and liabilities incurred in legal proceedings to which the director or executive officer was, or is threatened to be made, a party by reason of the fact that such director or executive officer is or was a director, executive officer, employee or agent of the Registrant, provided that such director or executive officer acted in good faith and in a manner that the director or executive officer reasonably believed to be in, or not opposed to, the best interest of the Registrant.

     

    The Registrant maintains insurance policies that indemnify its directors and officers against various liabilities arising under the Securities Act and the Exchange Act, that might be incurred by any director or officer in his capacity as such.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

     

     

     

    Item 8. Exhibits.

     

    Exhibit
    Number
      Description
         
    4.1   Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed on February 6, 2024).
         
    4.2   Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 of the Registrant’s Current Report on Form 8-K filed on February 6, 2024).
         
    4.3   Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 of the Registrant’s Registration Statement on Form S-1/A (File No. 333-276495), originally filed on January 29, 2024).
         
    5.1*   Opinion of Cooley LLP.
         
    23.1*   Consent of Independent Registered Public Accounting Firm.
         
    23.2*   Consent of Cooley LLP. Reference is made to Exhibit 5.1.
         
    24.1*   Power of Attorney. Reference is made to the signature page hereto.
         
    99.1   2024 Equity Incentive Plan (incorporated by reference to Exhibit 99.3 of the Registrant’s Registration Statement on Form S-8 (File No 333-276901) filed on February 6, 2024).
         
    99.2   Form of Option Grant Notice and Agreement, and Exercise Notice under the 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-276495), filed with the Commission on January 29, 2024).
         
    99.3   Form of RSU Award Grant Notice and Agreement under the 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-276495), filed with the Commission on January 29, 2024).
         
    99.4   2024 Employee Stock Purchase Plan (incorporated by reference to Exhibit 99.6 of the Registrant’s Registration Statement on Form S-8 (File No. 333-276901) filed on February 6, 2024).
         
    107*   Filing Fee Table.

     

    * Filed herewith.

     

    Item 9. Undertakings.

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.

     

    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the Registration Statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

     

     

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Mountain View, State of California, on this 16th day of March, 2026.

     

    ALTO NEUROSCIENCE, INC.  
         
    By: /s/ Amit Etkin  
      Amit Etkin, M.D., Ph.D.  
      President and Chief Executive Officer  

     

    POWER OF ATTORNEY

     

    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Amit Etkin, M.D., Ph.D. and Nicholas Smith and each of them, as his or her true and lawful attorney-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signatures   Title   Date
         
    /s/ Amit Etkin   President, Chief Executive Officer, and Chair of the Board of Directors   March 16, 2026
    Amit Etkin, M.D., Ph.D.   (Principal Executive Officer)    
         
    /s/ Nicholas Smith   Chief Financial Officer and Chief Business Officer   March 16, 2026
    Nicholas Smith   (Principal Financial Officer and Principal Accounting Officer)    
         
    /s/ Christopher Nixon Cox   Director   March 16, 2026
    Christopher Nixon Cox        
         
    /s/ Andrew Dreyfus   Director   March 16, 2026
    Andrew Dreyfus        
         
    /s/ Husseini Manji   Director   March 16, 2026
    Husseini Manji, M.D.        
         
    /s/ Raymond Sanchez   Director   March 16, 2026
    Raymond Sanchez, M.D.        
         
    /s/ Gwill York   Director   March 16, 2026
    Gwill York        

     

     

     

    Get the next $ANRO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANRO

    DatePrice TargetRatingAnalyst
    1/5/2026$30.00Buy
    Chardan Capital Markets
    11/17/2025Buy
    BTIG Research
    9/29/2025$15.00Buy
    Chardan Capital Markets
    10/23/2024$29.00 → $4.00Outperform → Neutral
    Wedbush
    10/23/2024Buy → Neutral
    Rodman & Renshaw
    9/3/2024$29.00Outperform
    Wedbush
    2/27/2024Outperform
    William Blair
    2/27/2024Outperform
    TD Cowen
    More analyst ratings

    $ANRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital Markets resumed coverage on Alto Neuroscience with a new price target

    Chardan Capital Markets resumed coverage of Alto Neuroscience with a rating of Buy and set a new price target of $30.00

    1/5/26 9:11:27 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Alto Neuroscience

    BTIG Research initiated coverage of Alto Neuroscience with a rating of Buy

    11/17/25 9:40:20 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Alto Neuroscience with a new price target

    Chardan Capital Markets initiated coverage of Alto Neuroscience with a rating of Buy and set a new price target of $15.00

    9/29/25 9:57:16 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANRO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alto Neuroscience Announces $120 Million Private Placement Financing

    – Financing led by Commodore Capital with participation from new and existing biotech focused investors – –  Alto expects to use the proceeds of the financing to support the development of ALTO-207 in Treatment Resistant Depression through a planned Phase 3 study and to a potential NDA submission – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the "PIPE") for gross proceeds of approximately

    3/16/26 7:03:00 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights

    – Acquisition of ALTO-207 targets Treatment-Resistant Depression (TRD) with a clinically-validated mechanism; Phase 2b trial on track to be initiated in the first half of 2026 – – External PAX-D study published in The Lancet Psychiatry demonstrated a 0.87 effect size for the core mechanism of ALTO-207; this effect represents a significantly larger effect size than current standard-of-care treatments – – ALTO-101 granted FDA Fast Track Designation for CIAS; Topline Phase 2 Proof-of Concept data expected around the end of 1Q 2026 – – Year-end cash balance of $177 million expected to fund planned operations into 2028, covering four key data readouts across Alto's precision psychiatry pip

    3/16/26 6:03:00 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum

    Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company's management team will participate in a virtual fireside chat at the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 12:00pm ET. The presentation will be accessible via a live webcast on the Events and Presentations page in the Investors section of Alto's website and a replay will be available following the presentation. About Alto Neuroscience Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobi

    3/13/26 8:03:00 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANRO
    SEC Filings

    View All

    Alto Neuroscience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Alto Neuroscience, Inc. (0001999480) (Filer)

    3/16/26 7:08:09 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Alto Neuroscience Inc.

    S-8 - Alto Neuroscience, Inc. (0001999480) (Filer)

    3/16/26 6:44:48 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Alto Neuroscience Inc.

    10-K - Alto Neuroscience, Inc. (0001999480) (Filer)

    3/16/26 6:07:28 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT AND CEO Etkin Amit covered exercise/tax liability with 6,227 shares, decreasing direct ownership by 0.50% to 1,233,949 units (SEC Form 4)

    4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

    3/3/26 7:16:05 PM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF FINANCIAL OFFICER & CBO Smith Nicholas Conrad covered exercise/tax liability with 2,806 shares, decreasing direct ownership by 10% to 24,060 units (SEC Form 4)

    4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

    3/3/26 7:15:26 PM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by PRESIDENT AND CEO Etkin Amit

    4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

    2/13/26 5:20:16 PM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF MEDICAL OFFICER Savitz Adam bought $190,833 worth of shares (15,000 units at $12.72) (SEC Form 4)

    4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

    7/11/24 4:15:04 PM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Smith Nicholas Conrad bought $100,628 worth of shares (6,150 units at $16.36), increasing direct ownership by 30% to 26,866 units (SEC Form 4)

    4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

    4/1/24 4:15:30 PM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANRO
    Leadership Updates

    Live Leadership Updates

    View All

    Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

    Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. "We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs," said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. "Ray brings an impress

    8/13/25 8:03:00 AM ET
    $ANRO
    $CERE
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Christopher Nixon Cox Named Chairman of High-Trend International Group

    SINGAPORE, March 13, 2025 /PRNewswire/ -- High-Trend International Group (NASDAQ:HTCO) (the "Company"), an international shipping company, today announced the appointment of Christopher Nixon Cox, as Chairman of the Company, effective immediately. Mr. Cox , a venture capitalist and advocate for socially impactful investing, will leverage his extensive expertise in global markets and sustainability to drive the Company's strategic growth in innovation-driven sectors. Mr. Jinyu Chang resigned as Chairman while remaining a director of the Company. The Company also named Mr. Bo Cui as its new Chief Legal Officer, underscoring its commitment to strengthening governance and global compliance amid

    3/13/25 9:00:00 AM ET
    $ANRO
    $HTCO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Marine Transportation
    Consumer Discretionary

    Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer

    – Mr. Hanley brings over two decades of leadership experience in product development and commercialization across a wide range of neuropsychiatric indications, including major depressive disorder and schizophrenia – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) today announced the expansion of the Company's leadership team with the addition of industry veteran Michael Hanley as chief operating officer (COO). Mr. Hanley brings over twenty-five years of leadership experience in the life sciences industry, with established expertise across corporate operations, product development, strategy, and commercialization, with relevant expertise in CNS/neuroscience-focused companies. As Alto's COO, M

    5/21/24 8:05:00 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANRO
    Financials

    Live finance-specific insights

    View All

    Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights

    – Acquisition of potentially best-in-class dopamine agonist combination product candidates, including ALTO-207, expands precision psychiatry pipeline; guided by compelling PAX-D study results published in The Lancet Psychiatry – – ALTO-207 adds expected late-stage readout in treatment resistant depression within current cash runway; planned Phase 2b trial, designed to be a potentially pivotal study expected to initiate by mid-2026 – – Topline data expected from Phase 2 proof-of-concept (POC) trial of ALTO-101 in schizophrenia in the second half of 2025; Phase 2b topline data readouts include ALTO-300 in MDD expected mid-2026 followed by ALTO-100 in bipolar depression expected in the sec

    8/13/25 4:10:00 PM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression

    –  Compelling PAX-D results guided Alto's acquisition of ALTO-207, designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – –  Alto plans to collaborate with National Health Service, PAX-D clinical sites for the planned Phase 2b trial of ALTO-207, designed to be a potentially pivotal study; trial expected to initiate by mid-2026 – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today highlighted The Lancet Psychiatry publication of data from the PAX-D study evaluating pramipexole in patients with treatment-r

    6/30/25 8:03:00 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

    – ALTO-207 (fka CTC-501) is a fixed-dose combination of pramipexole and ondansetron designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – – Alto has generated proprietary insights on dopamine biomarkers in depression suggesting that direct dopamine receptor activation with ALTO-207 has the potential to be a differentiated therapeutic approach for treatment resistant depression (TRD) – – CTC-501 met primary and secondary endpoints in a completed Phase 2a study in MDD, demonstrating significantly greater improvements on MADRS compared to placebo (Week 8 Cohen's d = 1.1, p<0.05) – – Alto expects to initiate a Phase 2b trial, design

    6/3/25 6:03:00 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Alto Neuroscience Inc.

    SC 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

    11/14/24 5:46:11 PM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Alto Neuroscience Inc.

    SC 13G - Alto Neuroscience, Inc. (0001999480) (Subject)

    11/14/24 7:00:29 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Alto Neuroscience Inc.

    SC 13G - Alto Neuroscience, Inc. (0001999480) (Subject)

    11/12/24 9:50:14 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care